Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.

Xie Y, Miranda SR, Hoskins JM, Hawke RL.

Molecules. 2017 Jan 15;22(1). pii: E142. doi: 10.3390/molecules22010142.

2.

Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.

He YJ, Winham SJ, Hoskins JM, Glass S, Paul J, Brown R, Motsinger-Reif A, McLeod HL.

Pharmacogenomics J. 2016 Jun;16(3):243-8. doi: 10.1038/tpj.2015.52. Epub 2015 Jul 21.

PMID:
26194361
3.

Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups.

He Y, Hoskins JM, Clark S, Campbell NH, Wagner K, Motsinger-Reif AA, McLeod HL.

Pharmacogenomics. 2015 Jul;16(8):817-24. doi: 10.2217/pgs.15.41. Epub 2015 Jun 17.

PMID:
26083016
4.

Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury.

Orrey DC, Halawa OI, Bortsov AV, Shupp JW, Jones SW, Haith LR, Hoskins JM, Jordan MH, Bangdiwala SI, Roane BR, Platts-Mills TF, Holmes JH, Hwang J, Cairns BA, McLean SA.

Clin J Pain. 2015 Jan;31(1):21-9. doi: 10.1097/AJP.0000000000000086.

5.

Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.

Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP Jr, McLeod HL, Davidson NE, Wolff AC.

Breast Cancer Res Treat. 2013 May;139(1):135-43. doi: 10.1007/s10549-013-2516-z. Epub 2013 Apr 16.

6.

Assessing the utility of whole genome amplified DNA as a template for DMET Plus array.

He YJ, Misher AD, Irvin W Jr, Motsinger-Reif A, McLeod HL, Hoskins JM.

Clin Chem Lab Med. 2012 Feb 14;50(8):1329-34. doi: 10.1515/cclm-2011-0747.

PMID:
22868796
7.

Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome.

Hoskins JM, Ong PS, Keku TO, Galanko JA, Martin CF, Coleman CA, Wolfe M, Sandler RS, McLeod HL.

PLoS One. 2012;7(7):e41954. doi: 10.1371/journal.pone.0041954. Epub 2012 Jul 27.

8.

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.

Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan KL, Xiong Y, Qin LX, Chiang DY.

Oncogene. 2013 Jun 20;32(25):3091-100. doi: 10.1038/onc.2012.315. Epub 2012 Jul 23.

9.

Galactose-α-1,3-galactose-specific IgE is associated with anaphylaxis but not asthma.

Commins SP, Kelly LA, Rönmark E, James HR, Pochan SL, Peters EJ, Lundbäck B, Nganga LW, Cooper PJ, Hoskins JM, Eapen SS, Matos LA, McBride DC, Heymann PW, Woodfolk JA, Perzanowski MS, Platts-Mills TA.

Am J Respir Crit Care Med. 2012 Apr 1;185(7):723-30. doi: 10.1164/rccm.201111-2017OC. Epub 2012 Jan 26.

10.

Catechol-O-methyltransferase genotype predicts pain severity in hospitalized burn patients.

Orrey DC, Bortsov AV, Hoskins JM, Shupp JW, Jones SW, Cicuto BJ, Hwang J, Jordan MH, Holmes JH, Haith LR, Roane BM, Diatchenko L, Cairns BA, McLean SA.

J Burn Care Res. 2012 Jul-Aug;33(4):518-23. doi: 10.1097/BCR.0b013e31823746ed.

11.

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK, Tien HC, Weigel R, Tauzie J, Shumba I, Lamba JK, Schuetz EG, McLeod HL, Kashuba AD, Corbett AH.

Pharmacogenomics. 2012 Jan;13(1):113-21. doi: 10.2217/pgs.11.132. Epub 2011 Nov 23.

12.

Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.

Thomas F, Motsinger-Reif AA, Hoskins JM, Dvorak A, Roy S, Alyasiri A, Myerson RJ, Fleshman JW, Tan BR, McLeod HL.

Br J Cancer. 2011 Nov 22;105(11):1654-62. doi: 10.1038/bjc.2011.442. Epub 2011 Nov 1.

13.

Copy number variants in pharmacogenetic genes.

He Y, Hoskins JM, McLeod HL.

Trends Mol Med. 2011 May;17(5):244-51. doi: 10.1016/j.molmed.2011.01.007. Epub 2011 Mar 8. Review.

14.

The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.

Metharom E, Galettis P, Manners S, Jelinek M, Liauw W, de Souza PL, Hoskins JM, Links M.

Asia Pac J Clin Oncol. 2011 Mar;7(1):65-74. doi: 10.1111/j.1743-7563.2010.01354.x. Epub 2010 Dec 30.

PMID:
21332653
15.

Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.

Thomas F, Hoskins JM, Dvorak A, Tan BR, McLeod HL.

Pharmacogenomics. 2010 Dec;11(12):1751-6. doi: 10.2217/pgs.10.170.

16.

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.

Schipani A, Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, Rodríguez Novoa S, Cuenca L, Soriano V, Chierakul N, Saguenwong N, Chuchuttaworn C, Hoskins JM, Dvorak AM, McLeod HL, Davies G, Khoo S, Back DJ, Di Perri G, Owen A.

Antimicrob Agents Chemother. 2010 Dec;54(12):5242-50. doi: 10.1128/AAC.00781-10. Epub 2010 Oct 4.

17.

Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.

Watson RG, Muhale F, Thorne LB, Yu J, O'Neil BH, Hoskins JM, Meyers MO, Deal AM, Ibrahim JG, Hudson ML, Walko CM, McLeod HL, Auman JT.

Eur J Cancer. 2010 Dec;46(18):3358-64. doi: 10.1016/j.ejca.2010.07.011. Epub 2010 Aug 18.

18.

Irinotecan pharmacogenomics.

Marsh S, Hoskins JM.

Pharmacogenomics. 2010 Jul;11(7):1003-10. doi: 10.2217/pgs.10.95. Review.

19.

Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.

Rakhra-Burris TK, Auman JT, Deverka P, Dressler LG, Evans JP, Goldberg RM, Havener TM, Hoskins JM, Jonas DE, Long KM, Motsinger-Reif AA, Irvin WJ, Richards KL, Roederer MW, Valgus JM, Riper Mv, Vernon JA, Zamboni WC, Wagner MJ, Walko CM, Weck KE, Wiltshire T, McLeod HL.

Pharmacogenomics. 2010 Jan;11(1):13-21. doi: 10.2217/pgs.09.167.

20.

Pharmacogenetics of breast cancer therapies.

Hertz DL, McLeod HL, Hoskins JM.

Breast. 2009 Oct;18 Suppl 3:S59-63. doi: 10.1016/S0960-9776(09)70275-9. Review.

21.

CYP2D6 and tamoxifen: DNA matters in breast cancer.

Hoskins JM, Carey LA, McLeod HL.

Nat Rev Cancer. 2009 Aug;9(8):576-86. doi: 10.1038/nrc2683. Review.

PMID:
19629072
22.

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F.

Pharmacogenomics. 2009 Jul;10(7):1139-46. doi: 10.2217/pgs.09.35.

23.

Influence of ethnicity on pharmacogenetic variation in the Ghanaian population.

Yen-Revollo JL, Van Booven DJ, Peters EJ, Hoskins JM, Engen RM, Kannall HD, Ofori-Adjei D, McLeod HL, Marsh S.

Pharmacogenomics J. 2009 Dec;9(6):373-9. doi: 10.1038/tpj.2009.28. Epub 2009 Jun 23.

PMID:
19546880
24.

Nevirapine hypersensitivity reaction: will the real HLA please stand up?

Hoskins JM, Roederer MW, McLeod HL.

Curr Opin Mol Ther. 2009 Jun;11(3):226-30. No abstract available.

PMID:
19479655
25.

UGT1A and irinotecan toxicity: keeping it in the family.

Hoskins JM, McLeod HL.

J Clin Oncol. 2009 May 20;27(15):2419-21. doi: 10.1200/JCO.2008.20.9478. Epub 2009 Apr 13. No abstract available.

PMID:
19364959
26.

Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M.

Clin Cancer Res. 2008 Mar 15;14(6):1788-96. doi: 10.1158/1078-0432.CCR-07-1472.

27.

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.

Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, Clarke SJ.

Clin Cancer Res. 2008 Feb 1;14(3):817-25. doi: 10.1158/1078-0432.CCR-07-0425.

28.

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL.

J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5. Epub 2007 Aug 28.

PMID:
17728214
29.

Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.

Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H.

Clin Pharmacol Ther. 2007 Jul;82(1):33-40. Epub 2007 May 9.

PMID:
17495881
30.

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

Michael M, Thompson M, Hicks RJ, Mitchell PL, Ellis A, Milner AD, Di Iulio J, Scott AM, Gurtler V, Hoskins JM, Clarke SJ, Tebbut NC, Foo K, Jefford M, Zalcberg JR.

J Clin Oncol. 2006 Sep 10;24(26):4228-35. Epub 2006 Aug 8.

PMID:
16896007
31.

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

Wong M, Balleine RL, Blair EY, McLachlan AJ, Ackland SP, Garg MB, Evans S, Farlow D, Collins M, Rivory LP, Hoskins JM, Mann GJ, Clarke CL, Gurney H.

J Clin Oncol. 2006 Jun 1;24(16):2448-55. Epub 2006 May 1.

PMID:
16651648
32.

The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells.

Holland ML, Panetta JA, Hoskins JM, Bebawy M, Roufogalis BD, Allen JD, Arnold JC.

Biochem Pharmacol. 2006 Apr 14;71(8):1146-54. Epub 2006 Feb 2.

PMID:
16458258
33.
34.

Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.

Wong M, Evans S, Rivory LP, Hoskins JM, Mann GJ, Farlow D, Clarke CL, Balleine RL, Gurney H.

Clin Pharmacol Ther. 2005 Jan;77(1):33-42.

PMID:
15637529
35.

Effect of short-term morphine exposure on P-glycoprotein expression and activity in cancer cell lines.

Pajic M, Bebawy M, Hoskins JM, Roufogalis BD, Rivory LP.

Oncol Rep. 2004 May;11(5):1091-5.

PMID:
15069552
36.

Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.

Hoskins JM, Shenfield GM, Gross AS.

Eur J Clin Pharmacol. 2003 Nov;59(8-9):611-4. Epub 2003 Sep 12.

PMID:
13680037
37.

High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two metabolites in plasma.

Hoskins JM, Gross AS, Shenfield GM, Rivory LP.

J Chromatogr B Biomed Sci Appl. 2001 Apr 25;754(2):319-26.

PMID:
11339275
38.

The erythromycin breath test for the prediction of drug clearance.

Rivory LP, Slaviero KA, Hoskins JM, Clarke SJ.

Clin Pharmacokinet. 2001;40(3):151-8. Review.

PMID:
11327195
39.

Optimizing the erythromycin breath test for use in cancer patients.

Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, Millward MJ, Bishop JF, Clarke SJ.

Clin Cancer Res. 2000 Sep;6(9):3480-5.

40.

Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.

Hoskins JM, Shenfield GM, Gross AS.

Br J Clin Pharmacol. 1998 Nov;46(5):499-504. Erratum in: Br J Clin Pharmacol 1999 May;47(5):603.

41.

Modified high-performance liquid chromatographic method to measure both dextromethorphan and proguanil for oxidative phenotyping.

Hoskins JM, Shenfield GM, Gross AS.

J Chromatogr B Biomed Sci Appl. 1997 Aug 15;696(1):81-7.

PMID:
9300912
42.

Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients.

Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA.

AIDS. 1994 Mar;8(3):333-7.

PMID:
8031511
43.

Human rabies immunoglobulin assayed by the rapid fluorescent focus inhibition test suppresses active rabies immunization.

Glück R, Wegmann A, Keller H, Hoskins JM, Germanier R.

J Biol Stand. 1987 Apr;15(2):177-83.

PMID:
3298263
44.

Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells.

Glück R, Hoskins JM, Wegmann A, Just M, Germanier R.

Dev Biol Stand. 1986;65:29-35.

PMID:
3556774
45.

A highly purified and concentrated duck embroy rabies vaccine: a preliminary report.

Schell KR, Fürst M, Haberstich HU, Mischler R, Hoskins JM, Wegmann A.

J Biol Stand. 1980;8(2):97-106. No abstract available.

PMID:
7410442
46.

Laboratory techniques in rabies: duck-embryo vaccine.

Hoskins JM.

Monogr Ser World Health Organ. 1973;(23):243-55. No abstract available.

PMID:
4219488
47.

Immunological relationships of some oncogenic DNA viruses. II. Primary tumour inhibition studies.

Potter CW, Oxford JS, Hoskins JM.

Arch Gesamte Virusforsch. 1969;27(1):87-93. No abstract available.

PMID:
4310713
48.

Immunological relationships of some oncogenic DNA viruses. I. Transplantation immunity studies.

Potter CW, Hoskins JM, Oxford JS.

Arch Gesamte Virusforsch. 1969;27(1):73-86. No abstract available.

PMID:
4310712
49.

Behaviour of rubella virus in human diploid cell strains. II. Studies of infected cells.

Hoskins JM, Plotkin SA.

Arch Gesamte Virusforsch. 1967;21(3):296-308. No abstract available.

PMID:
5600960
50.

Chromosome studies of human cells infected in utero and in vitro with rubella virus.

Chang TH, Moorhead PS, Boué JG, Plotkin SA, Hoskins JM.

Proc Soc Exp Biol Med. 1966 May;122(1):236-43. No abstract available.

PMID:
5949790

Supplemental Content

Loading ...
Support Center